DMT clinical trials in the registry
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
N,N-dimethyltryptamine, usually shortened to DMT, is a tryptamine found in many plants and animals. Registry searches for the abbreviation DMT also return unrelated records about disease-modifying therapy for multiple sclerosis; those records are removed before anything is counted on this page.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 37 registered DMT studies are counted on this page.
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 6 | 16% |
| Not yet recruiting | 1 | 3% |
| Active, not recruiting | 3 | 8% |
| Completed | 24 | 65% |
| Terminated | 1 | 3% |
| Withdrawn | 1 | 3% |
| Status not reported | 1 | 3% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 2 | 5% |
| Phase 1 | 26 | 70% |
| Phase 2 | 6 | 16% |
| Not applicable | 1 | 3% |
| Not reported | 2 | 5% |
Countries
Country is taken from the study's linked research site. 0 of 37 records have no country on file. The top 8 countries are shown.
| Country | Studies | Share |
|---|---|---|
| Switzerland | 10 | 27% |
| United States | 9 | 24% |
| Brazil | 5 | 14% |
| Netherlands | 5 | 14% |
| United Kingdom | 4 | 11% |
| Argentina | 2 | 5% |
| Czechia | 1 | 3% |
| Spain | 1 | 3% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 15 |
| 2020 to 2023 | 19 |
| 2015 to 2019 | 2 |
| 2010 to 2014 | 1 |
Study design
- 35 interventional and 2 observational studies.
- Median planned or actual enrolment is 36 participants (range 14 to 200, across 36 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Healthy volunteers | 17 |
| Depression and mood | 8 |
| Anxiety | 3 |
| Alcohol use | 1 |
| Pain and headache | 1 |
Most recently started studies
The 25 studies with the latest start dates, shown newest first. The order is not a ranking and says nothing about quality. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07693257 | Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) | Not yet recruiting | Phase 1 | United States | 2026-09 |
| NCT07562191 | Inhaled DMT for Major Depressive Disorder | Recruiting | Phase 2 | Brazil | 2026-08 |
| NCT07444788 | Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants | Recruiting | Phase 1 | Switzerland | 2026-03 |
| NCT06810765 | Trifecta Research Study | Withdrawn | Phase 2 | United States | 2025-09 |
| NCT06927076 | Antidepressant Response of DMT Masked With Propofol | Recruiting | Not applicable | Switzerland | 2025-08 |
| NCT06070649 | The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) | Recruiting | Phase 1 | United States | 2025-08 |
| NCT06899334 | Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants | Recruiting | Phase 1 | Switzerland | 2025-04 |
| NCT06671977 | Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans | Recruiting | Phase 1 | United States | 2025-03 |
| NCT06180759 | Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants | Completed | Phase 1 | Switzerland | 2025-01 |
| NCT06812221 | Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI | Completed | Phase 1 | Argentina | 2024-12 |
| NCT06624137 | Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics | Terminated | Not reported | United States | 2024-12 |
| NCT06816667 | Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety | Completed | Phase 1 | Argentina | 2024-10 |
| NCT05695495 | Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study) | Completed | Phase 1 | Switzerland | 2024-06 |
| NCT06051721 | A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) | Completed | Phase 2 | United States | 2024-05 |
| NCT06252506 | Molecular Imaging Study of Harmine/DMT: a Basic Research Approach | Completed | Phase 1 | Switzerland | 2024-01 |
| NCT06094907 | Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression | Completed | Phase 2 | Brazil | 2023-10 |
| NCT05800860 | A Trial of GH001 in Patients With Treatment-resistant Depression | Completed | Phase 2 | Czechia | 2023-05 |
| NCT05901012 | Safety and Tolerability of DMT in Healthy Adults | Completed | Phase 1 | Brazil | 2023-04 |
| NCT05780216 | Mindfulness and Psychedelics | Completed | Early Phase 1 | Switzerland | 2023-02 |
| NCT05559931 | Single and Repeat Doses of DMT in Healthy Subjects | Active, not recruiting | Phase 1 | Netherlands | 2023-01 |
| NCT05644093 | IM and IV SPL026 Drug Product in Healthy Participants | Completed | Phase 1 | United Kingdom | 2023-01 |
| NCT05698095 | Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers | Completed | Phase 1 | United States | 2022-12 |
| NCT05753956 | Safety and Pharmacokinetics of GH002 in Healthy Volunteers | Completed | Phase 1 | Netherlands | 2022-12 |
| NCT05553691 | SPL026 With or Without SSRIs in Participants With MDD | Completed | Phase 1 | United Kingdom | 2022-12 |
| NCT05384678 | Acute Dose-dependent Effects of DMT in Healthy Subjects | Completed | Phase 1 | Switzerland | 2022-11 |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals.
Records about disease-modifying therapy, multiple sclerosis and similar unrelated uses of the abbreviation DMT are removed before counting. Studies of 5-MeO-DMT and ayahuasca have their own hubs.
Other substance hubs
Psilocybin | MDMA | LSD | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable